At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 25 enrolled
Drug / intervention
Bevacizumab +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 2 Investigator Initiated Study to Determine the Efficacy and Safety of TVB- 2640 in Combination With Bevacizumab in Patients With First Relapse of High Grade Astrocytoma
The University of Texas Health Science Center at San Antonio·interventional·Posted Jan 26, 2017·Updated Jun 15, 2023
In Brief
A Phase 2 clinical trial evaluating Bevacizumab and TVB-2640 for Astrocytoma. Completed, enrolled 25 participants across 1 site.
Detailed Summary
Randomized phase 2 study TVB-2640 in combination with Bevacizumab versus Bevacizumab alone.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAstrocytoma
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
2017201820192020202120222023202420252026
First PostedJan 2017
Enrollment StartMay 2017
Primary CompletionApr 2020
Study CompletionApr 2021
TodayJul 2026
First PostedJan 26, 2017
Enrollment StartMay 18, 2017
Primary CompletionApr 4, 2020
Study CompletionApr 5, 2021
TodayJul 2, 2026
Enrollment to primary: 2.9 yearsPosted 9.4 years ago
Interventions
Bevacizumabdrug
Bevacizumab is FDA approved as a treatment for recurrent Glioblastoma following failure of radiation therapy and temozolomide.
TVB-2640drug
TVB-2640 is a potent and reversible inhibitor of the FASN enzyme. TVB-2640 inhibits the β-ketoacyl reductase (KR) enzymatic activity of the FASN enzyme.